Endometriosis patient creates Noha, a wearable non invasive device to relief period cramps and period pain

Ovira, founded by Alice Williams, has emerged as a trailblazing company in the field of menstrual pain relief, harnessing the power of TENS (Transcutaneous Electrical Nerve Stimulation) technology with their innovative product, the Noha Period Cramp Relief Device. Established in 2018 in Sidney, Australia, the company set out to address the unmet need for effective, non-invasive solutions for women experiencing menstrual cramps.

Alice Williams belongs to the 10% of women worldwide who suffers the challenges of endometriosis, enduring years of excruciating period cramps, blackouts, vomiting, and days confined to bed each month. Frustrated by the lack of effective solutions offered by traditional solutions for period cramps and acute menstrual pain, such as painkillers, contraceptive pills or hot water bottles, Alice embarked on a personal journey to develop a remedy that could truly alleviate the suffering. Her determination and innovative spirit led to the founding of Ovira, a company dedicated to transforming her own struggle into a solution that positively impacts the lives of women facing similar experiences of menstrual pain.

Ovira's Noha Period Cramp Relief Device, their flagship product priced at around 140€ and sold worldwide, offers targeted relief for menstrual cramps and extends its effectiveness to address a broader range of pain conditions. This versatile device, with around 16,870 verified customer’s reviews, has the capability to provide symptomatic pain relief for chronic, acute, or post-operative pain. By leveraging TENS technology, the device emits gentle electrical pulses through specially designed pads, effectively targeting and alleviating pain associated with various conditions. Whether it's chronic pain, acute discomfort, or post-operative recovery, Ovira's period cramp relief device offers a flexible and non-invasive solution for individuals seeking relief from diverse sources of pain.

The impact of the Noha Device has been significant, with around 30K of users worldwide. Ovira not only prioritizes the efficacy of their device but also offers a 100-day risk-free trial, ensuring a seamless and satisfying customer experience. Ovira's commitment to clinical testing and FDA approval as a Class IIa medical device further solidifies its impact, ensuring its safety, efficacy, and reliability.

Adapted from:
https://eu.ovira.com/
https://www.smartcompany.com.au/startupsmart/news/ovira-alice-williams-f...
https://www.youtube.com/watch?v=0FWSYB9NLLU&t=2s